Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 159

1.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00326-18. doi: 10.1128/AAC.00326-18. [Epub ahead of print]

PMID:
29891610
2.

Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.

Mogalian E, Brainard DM, Osinusi A, Moorehead L, Murray B, Ling KHJ, Perry R, Curtis C, Lawitz E, Lasseter K, Marbury T, Mathias A.

Clin Pharmacokinet. 2018 Mar 8. doi: 10.1007/s40262-018-0645-6. [Epub ahead of print]

PMID:
29520729
3.

Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.

Kosloski MP, Zhao W, Marbury TC, Preston RA, Collins MG, Pugatch D, Mensa F, Kort J, Liu W.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01990-17. doi: 10.1128/AAC.01990-17. Print 2018 Mar.

PMID:
29263061
4.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.

Marshall WL, Feng HP, Wenning L, Garrett G, Huang X, Liu F, Panebianco D, Caro L, Fandozzi C, Lasseter KC, Preston RA, Marbury T, Butterton JR, Iwamoto M, Yeh WW.

Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):321-329. doi: 10.1007/s13318-017-0451-9.

PMID:
29247332
5.

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.

Kusawake T, Kowalski D, Takada A, Kato K, Katashima M, Keirns JJ, Lewand M, Lasseter KC, Marbury TC, Preston RA.

Adv Ther. 2017 Dec;34(12):2612-2624. doi: 10.1007/s12325-017-0643-3. Epub 2017 Nov 13.

6.

Impact of siponimod on vaccination response in a randomized, placebo-controlled study.

Ufer M, Shakeri-Nejad K, Gardin A, Su Z, Paule I, Marbury TC, Legangneux E.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 13;4(6):e398. doi: 10.1212/NXI.0000000000000398. eCollection 2017 Nov.

7.

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.

Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec.

8.

Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.

Albrecht D, Turakhia MP, Ries D, Marbury T, Smith W, Dillon D, Milner PG, Midei MG.

Thromb Haemost. 2017 Nov;117(11):2026-2033. doi: 10.1160/TH16-10-0815. Epub 2017 Nov 30.

PMID:
28933798
9.

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.

Marbury TC, Berg JK, Dove LS, Covington PS.

J Clin Pharmacol. 2017 Nov;57(11):1454-1459. doi: 10.1002/jcph.964. Epub 2017 Jul 18. No abstract available.

10.

Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
.

Min KC, Lasseter KC, Marbury TC, Wrishko RE, Hanley WD, Wolford DG, Udo de Haes J, Reitmann C, Gutstein DE.

Int J Clin Pharmacol Ther. 2017 Sep;55(9):746-752. doi: 10.5414/CP203025.

PMID:
28679468
11.

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.

Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K.

Clin Pharmacokinet. 2017 Nov;56(11):1381-1390. doi: 10.1007/s40262-017-0528-2.

12.

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.

Marbury T, Fox J, Kaelin B, Pavliv L.

Drug Des Devel Ther. 2017 Feb 13;11:373-382. doi: 10.2147/DDDT.S125459. eCollection 2017.

13.

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.

Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M.

J Clin Pharmacol. 2017 Jun;57(6):777-783. doi: 10.1002/jcph.857. Epub 2016 Dec 27.

PMID:
28026013
14.

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.

Dymond AW, Martin P, So K, Huang Y, Severin P, Holmes V, Mariani G, Marbury T.

J Clin Pharmacol. 2017 May;57(5):592-605. doi: 10.1002/jcph.848. Epub 2016 Dec 26.

15.

Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.

Paglialunga S, Offman E, Ichhpurani N, Marbury TC, Morimoto BH.

Expert Rev Clin Pharmacol. 2017 Mar;10(3):273-283. doi: 10.1080/17512433.2017.1274651. Epub 2017 Jan 29. Review.

PMID:
27998190
16.

Pharmacokinetic profile of defibrotide in patients with renal impairment.

Tocchetti P, Tudone E, Marier JF, Marbury TC, Zomorodi K, Eller M.

Drug Des Devel Ther. 2016 Aug 16;10:2631-41. doi: 10.2147/DDDT.S112181. eCollection 2016.

17.

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.

Hoover R, Marbury TC, Preston RA, Quintas M, Lawrence LE, Paulson SK, Luke DR, Cammarata SK.

J Clin Pharmacol. 2017 Mar;57(3):328-335. doi: 10.1002/jcph.817. Epub 2016 Oct 14.

18.

Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.

Khatri A, Dutta S, Marbury TC, Preston RA, Rodrigues L Jr, Wang H, Awni WM, Menon RM.

Clin Pharmacokinet. 2017 Feb;56(2):153-163. doi: 10.1007/s40262-016-0429-9.

PMID:
27389403
19.

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P.

PLoS One. 2016 Jun 21;11(6):e0157335. doi: 10.1371/journal.pone.0157335. eCollection 2016.

20.

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment.

de Jong J, Skee D, Hellemans P, Jiao J, de Vries R, Swerts D, Lawitz E, Marbury T, Smith W, Sukbuntherng J, Mannaert E.

Leuk Lymphoma. 2017 Jan;58(1):185-194. Epub 2016 Jun 7.

PMID:
27267254

Supplemental Content

Loading ...
Support Center